EXAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exact Sciences Corp (EXAS) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is currently trading close to its acquisition price of $105 per share, which limits upside potential. Additionally, analysts have downgraded the stock to Hold due to the acquisition, and there are no significant positive catalysts or proprietary trading signals to suggest a strong buy opportunity.
The stock's technical indicators are mixed. The MACD histogram is negative and contracting, indicating bearish momentum. RSI is neutral at 67.088, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are close to the current price, with a pivot at 102.85 and resistance at 103.388. Overall, the technicals do not suggest a strong entry point.
The company has shown strong revenue growth in Q3 2025, with a 20.05% YoY increase. Abbott's acquisition of Exact Sciences for $105 per share provides a clear exit price for shareholders.
The acquisition limits upside potential as the stock is trading near the agreed price of $105 per share. Analysts have downgraded the stock to Hold, and hedge funds have significantly increased selling activity. Additionally, the company's net income and EPS have declined sharply YoY, indicating financial challenges.
In Q3 2025, revenue increased by 20.05% YoY to $850.74M. However, net income dropped by 48.76% YoY to -$19.59M, and EPS declined by 52.38% YoY to -$0.1. Gross margin slightly decreased to 68.64%. While revenue growth is strong, profitability metrics have worsened significantly.
Analysts have downgraded the stock to Hold from Buy following the acquisition announcement. The price target is consistently set at $105 per share, aligning with the acquisition price. There are no recent upgrades or positive revisions in ratings.
